Stacie B. Dusetzina, Ph.D.
Pharmaceutical Policy, Pharmacoepidemiology, Cancer Outcomes Research
Dr. Dusetzina is a professor in the Department of Health Policy and an Ingram professor of cancer research at Vanderbilt University School of Medicine. She is a health services researcher focusing on the intersection between health policy, epidemiology, and economics related to prescription drugs. Dr. Dusetzina’s work has contributed to the evidence base for the role of drug costs on patient access to care and policy changes that might improve patient access to high-priced drugs.
She has been recognized for her work at a national level, including regularly engaging with the press on the topic of drug pricing and policy, co-authoring a National Academies of Sciences, Engineering and Medicine report on “Making Medicines Affordable”, and being selected to serve on the Medicare Payment Advisory Commission in 2021.
Recent & Highlighted Research
Dusetzina SB. Improving the Affordability of Prescription Drugs for Medicare Beneficiaries. JAMA Intern Med. 2024 Dec 23. doi: 10.1001/jamainternmed.2024.6915. Epub ahead of print. PMID: 39714864.
Dusetzina SB, David FS. Cancer Drug Access and Innovation Under the Inflation Reduction Act-A Balancing Act. JAMA Oncol. 2024 Dec 1;10(12):1614-1615. doi: 10.1001/jamaoncol.2024.4745. PMID: 39446358.
Jazowski SA, Nayak RK, Dusetzina SB. The high costs of anticancer therapies in the USA: challenges, opportunities and progress. Nat Rev Clin Oncol. 2024 Dec;21(12):888-899. doi: 10.1038/s41571-024-00948-1. Epub 2024 Oct 4. Erratum in: Nat Rev Clin Oncol. 2024 Dec;21(12):903. doi: 10.1038/s41571-024-00958-z. PMID: 39367130.
Blendon RJ, Blumenthal D, Glied S, Sommers BD, Rosenthal MB, McWilliams JM, Dusetzina SB, Figueroa JF, Yearby R, Alsan M, Kim JJ, Rubin EJ. Critical Health Care Challenges for the Next U.S. President. N Engl J Med. 2024 Oct 17;391(15):e36. doi: 10.1056/NEJMp2412959. PMID: 39413384.
McWilliams JM, Dusetzina SB. Affordability of Health Care in the United States - Old Problems Awaiting a New Administration. N Engl J Med. 2024 Oct 17;391(15):1372-1374. doi: 10.1056/NEJMp2410638. Epub 2024 Oct 2. PMID: 39357040.
Glaus CEG, Serra-Burriel M, Dusetzina SB, Vokinger KN. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022). Ann Intern Med. 2024 Oct;177(10):1442-1444. doi: 10.7326/ANNALS-24-00614. Epub 2024 Sep 3. PMID: 39222511.